A Phase II Randomized Open label Study of High Dose Interleukin 2 vs High Dose Interleukin 2 plus Entinostat in Untreated Advanced Renal Cell Carcinoma (GU17-289)

Study on the Effects of High Dose Investigational Medication in Renal Cell Carcinoma

Recruiting
18 years - 100 years
All
Phase N/A
1 Location

Brief description of study.

The purpose of this study is to compare any good and bad effects of using a high dose Interleukin (IL-2) and Entinostat to using IL-2 alone. The addition of Entinostat to high dose IL-2 could shrink your cancer/prevent it from returning for a longer period of time but it could also cause side effects. This study will allow the researchers to know whether this different approach is better, the same, or worse than the usual approach.

Detailed description of study

The purpose of this study is to estimate and compare progression free survival (PFS) in patients receiving high dose interleukin 2 or high dose interleukin 2 plus entinostat.
Participants will not be paid for their participation.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: renal cell carcinoma
  • Age: 18 years - 100 years
  • Gender: All

Inclusion Criteria
In order to be eligible to take part in this trial, patients must meet the following criteria:

  • Patients must have pathological diagnosis of renal cell carcinoma that is metastatic or surgically unresectable. The histology must be clear cell carcinoma or predominant clear cell carcinoma.
  • Up to two prior therapies for RCC are allowed. One prior therapy must contain an immune checkpoint inhibitor. Prior palliative radiation to metastatic lesion(s) is permitted, provided there is at least one measurable and/or evaluable lesion(s) that has not been irradiated.

For a full list of participation criteria, please visit clinicaltrials.gov.

Updated on 19 Feb 2024. Study ID: 1712301349

This study investigates the effects of using a high dose of a protein called interleukin (IL-2) along with a substance called Entinostat in treating renal cell carcinoma, a type of kidney cancer. The purpose of this study is to see if adding Entinostat to IL-2 can help control cancer better than using IL-2 alone. Renal cell carcinoma is a cancer that starts in the kidneys and can spread to other parts of the body.

Participants in the study will receive either high dose IL-2 alone or high dose IL-2 combined with Entinostat. This will help researchers compare how well these treatments work. Participants will not be paid for their participation in this study.

  • Who can participate: Adults with metastatic or surgically unresectable renal cell carcinoma, specifically clear cell carcinoma, can participate. Patients should have had up to two prior therapies, including one with an immune checkpoint inhibitor, and must have measurable lesions.
  • Study details: Participants will receive either high dose IL-2 alone or high dose IL-2 with Entinostat. A placebo is not used in this study.

Find a site

Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact label
Race
Ethnicity
Other language

Default Content Message Here